Article
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2017
Goey K K H, Elias S G, van Tinteren H, Laclé M M, Willems S M, Offerhaus G J A, de Leng W W J, Strengman E, Ten Tije A J, Creemers G-J M, van der Velden A, de Jongh F E, Erdkamp F L G, Tanis B C, Punt C J A, Koopman M
Abstract excerpt
BACKGROUND: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without compromising quality of life. In this post hoc analysis with updated follow-up and data regarding sidedness, we defined subgroups according to RAS/BRAF mutation status...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.